BioMaxima S.A.

Warsaw Stock Exchange BMX.WA

BioMaxima S.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2023: USD 1.08 M

BioMaxima S.A. Net Cash Used Provided By Financing Activities is USD 1.08 M for the year ending December 31, 2023, a 124.45% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

BioMaxima S.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2022 was USD -4.41 M, a -944.93% change year over year.
BioMaxima S.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2021 was USD 521.97 K, a 31.62% change year over year.
BioMaxima S.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2020 was USD 396.58 K, a 139.17% change year over year.
BioMaxima S.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2019 was USD -1.01 M, a -125.70% change year over year.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

Warsaw Stock Exchange: BMX.WA

BioMaxima S.A.

CEO	Mr. Lukasz Urban
IPO Date	July 21, 2010
Location	Poland
Headquarters	ul. VetterOw 5
Employees	115
Sector	Consumers Staples
Industries Personal Care Biotechnology Cleaning Supplies Fertilizers Medical Instruments Petrochemicals Pharmaceuticals Plastics

Description

BioMaxima S.A. manufactures and distributes reagents for in vitro diagnostics in Poland. Its primary products include diagnostic reagents and analyzers for clinical chemistry; rapid tests and readers for detecting infectious diseases, cancer markers, cardiac markers, and drugs of abuse; urine analysis systems; hematology analyzers and reagents; ionselective analyzers and reagents; reagents and immunological analyzers of cardiac markers; glucometers for professional use; and analyzers for gasometric tests and critical blood parameters tests. The company also provides surfaces and air controls; antibiotics discs and MIC strips; and chromogenic, dehydrated, and prepared culture media; and additives and supplements for media. It supplies its products to approximately 2,000 laboratories in Poland, as well as exports in the international markets. BioMaxima S.A. was founded in 2002 and is based in Lublin, Poland.

Key trends

Past 5 years